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ABSTRACT 
Objective: The present study was conducted with the objective of analyzing the efficacy of triple-drug combination therapy (formoterol, 
ciclesonide, tiotropium) by comparing it with double drug combination therapy (formoterol, budesonide). 
Methods: A prospective observational study was conducted. Sixty patients were enrolled, and divided into two groups of thirty each; one group was 
treated with the double-drug and the other with a triple drug combination. FEV1 and FVC pre-and post-treatment in either group were assessed 
spirometrically. Score ranges of 0-10, 11-20 and 21-30 were allotted to mild, moderate and severe categories and results were analyzed statistically. 
Results: Of the 60 patients recruited, 61-70 y olds constituted the majority (35%) of the population. Males (63.3%) were more in number compared 
to females (36.6%). Twenty-three of thirty-eight men smoked (60.5%); there were no female smokers. Common symptoms included cough (93.3%), 
dyspnoea (85%), fever (45%) and haemoptysis (15%). Hypertension accounted for 70% of patient comorbidities, followed by diabetes (60%) and 
cardiovascular diseases (40%). Three months after treatment with triple therapy, a significant increase in the differences of means of both FEV1 
(14.27) and FVC (14.90) values was observed. Further analysis based on score ranges demonstrated that triple therapy administration markedly 
reduced the number of patients suffering from severe COPD. 
Conclusion: Our comparative analysis indicated that triple therapy was more effective in improving lung function, enhancing patients’ quality of life 
(evidenced from score ranges) thereby reducing mortality. While much is known about the greater effectiveness of triple over dual therapy, 
researchers to formulate the most effective triple therapy are in progress.  
Keywords: Chronic obstructive pulmonary disease (COPD), Inhaled corticosteroids, Long-acting β2 agonist, Long-acting muscuranic antagonist, Spirometry 




The history of COPD can be traced back to Dr. Rene Laënnec, who 
was the first to precisely establish a relationship between chronic 
bronchitis and emphysema [1]. Over the years, advancements in the 
understanding of the disease, its explicit etiology, detailed pathology 
and distinct pharmacotherapy have aided in improving patient 
outcomes [1, 2]. In 1962, the American Thoracic Society Committee 
defined emphysema as “an anatomic alteration of the lung 
characterized by an abnormal enlargement of the airspace distal to 
the terminal, non-respiratory bronchiole accompanied by 
destruction of the alveolar walls” [3]. Chronic bronchitis on the 
other hand, was defined in 1965 as “a cough with expectoration that 
has occurred on most days during at least three consecutive months 
for more than two successive years” [4]. As of now, the Global 
Initiative for Chronic Obstructive Lung Disease (GOLD) defines COPD 
as “common, preventable and treatable disease that is characterized 
by persistent respiratory symptoms and airflow limitation that is due 
to airway and/or alveolar abnormalities usually caused by significant 
exposure to noxious particles or gases” [5].  
Analogous to the discovery of COPD which coursed gradually 
through decades, the establishment of a peculiar treatment therapy 
for the disease took years to develop. Until the 1950s, no specific 
treatment was authorized, excepting a few sedatives and antibiotics. 
Corticosteroids were almost never used. During the 1960s, 
mechanical ventilators and long-term oxygen therapy measures 
began to be extensively studied and trialled and were shown to 
improve outcomes, hence used in patients with longstanding COPD 
[1]. Smoking as a cause of respiratory derangements was 
authenticated only in the late 1990s [6]. By the end of the twentieth 
century, available treatment options included smoking cessation, 
antibiotics, bronchoactive agents and steroids [7]. 
Ranked as the fifth leading cause of death in 2002 [8], COPD accounted 
for six percent of the world’s mortality in 2012 [5]. By 2030, it is 
expected to secure the fourth position and may account for 7.8% of total 
deaths globally [8]. The disease is more probable in high-income 
countries [9]. The development of COPD is multifactorial, risk factors 
implicated in its etiology include: cigarette smoking, indoor (biomass) or 
outdoor environmental pollutants, genetic factors and recurrent 
juvenescent infections of the lower respiratory tract [5, 10]. Spirometric 
irregularity, flawed arterial blood gas tests and other findings on 
physical examination hint to the presence of COPD [5, 10, 11]. 
Present day medications used to treat COPD include beta-agonists, 
parasympatholytics, methylxanthines, corticosteroids, phosphor-
diesterase inhibitors, and combination therapies incorporating two 
or more drugs [12]. There has been some controversy regarding the 
effectiveness of one combination regimen over the other. Therefore, 
the current research was conducted with the objective of comparing 
dual drug with triple-drug therapy and evaluating the efficacy of 
either regimen. Spirometric analysis was utilized for obtaining 
reliable results. 
MATERIALS AND METHODS 
The present prospective observational study was carried out from 
September 2014 to February 2015 in the Department of 
Pulmonology, Krishna Institute of Medical Sciences (KIMS) Hospital, 
Secunderabad, Telengana, India. Data for this study was collected 
prospectively from case sheets and from consent-obtained 
questionnaires distributed to patients in both inpatient (IP) and 
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outpatient (OP) departments. The study was approved by the KIMS 
Foundation and Research Centre Ethics Committee (KFRC/EC/ 
APR/024/2015, dated 14.02.15). All patients diagnosed with chronic 
obstructive pulmonary disease and aged 40 y or above were the 
study population. Pregnant or lactating women, patients who 
portrayed reluctance for enrollment, and those who failed to show 
up for subsequent review were excluded from the study. 
Study procedure 
The study was conducted on 60 patients suffering from COPD. The 
participants were divided into two groups of 30 each. One group 
received a dual combination inhaler of formoterol 6 µg and 
budesonide 100 µg, while the other group was given a triple drug 
combination inhaler of formoterol 6 µg, ciclesonide 200 µg and 
tiotropium 9 µg. Before the commencement of treatment, patients’ 
FEV1 and FVC values were recorded, while ‘symptoms encountered’ 
were assessed with the aid of a questionnaire validated by a 
registered clinician. Patients were required to appear for a follow-up 
three months succeeding initiation of therapy. During follow-up 
visits, post-treatment FEV1 and FVC values were charted, while the 
distribution of questionnaires analogous to those previously 
distributed, enabled reassessment of any persisting symptoms. Data 
collected was then subjected to statistical analysis. 
Statistical analysis 
We used Microsoft Excel 2007 and mean of samples to compute the 
observed values of pre-and post-treatment.  
The following parameters were analysed statistically:  
• FEV1 and FVC values pre-and post-treatment in dual therapy. 
• FEV1 and FVC values pre-and post-treatment in triple therapy. 
A comparative pre-and post-treatment analysis in either group was 
then done to assess any improvement in symptoms. 
 
 
Fig. 1: Demographic distribution of COPD patients 
RESULTS 
Demographic distribution of patients 
In the present study, a total of sixty patients were enrolled and 
distributed according to their age (<50 y or>50 y) and sex. Fifteen 
patients were aged below 50 y (9 males and 6 females), while the 
remaining 45 were above 50 y of age (29 males and 16 females). 
Demographic distribution of patients is shown in fig. 1.  
Age distribution of patients 
Age distribution of patients was enumerated and it was found that 
35% of the diseased population was aged between 61 and 70 y. This 
was followed by the age group of 51-60 y who constituted another 
25% of the total. Age groups of 41-50 and 71-80 y olds constituted 
15% each. The least prone was the age range of 81-90 y (10%).  
Gender wise distribution of patients 
The sample consisted of 38 men (majority of the sample size) and 22 
women suffering from the chronic illness. The percentages in men 
and women were reported as 63.33% and 36.67% respectively.  
Smokers and non-smokers having COPD 
From the 60 patients enrolled in the study, 38 were males and 22 
were females. No female smokers were documented in this 
prospective study. However, among the 38 men, there were 23 
smokers and 15 non-smokers. Smokers accounted for about 38.33% 
while non-smokers, from the total, made up the remaining 61.67%.  
Presence of symptoms in COPD patients 
We categorised the manifestations of COPD as cough, shortness of 
breath, fever and haemoptysis. From a sum of 60 patients, 56 
experienced cough, accounting for 93.33%, 51 suffered with 
shortness of breath, accounting for 85%, 27 presented with pyrexia, 
constituting 45%, and 9 patients experienced haemoptysis, 
accounting for 15% of the total subjects.  
Comorbidities in COPD 
Comorbidities such as hypertension, heart diseases, diabetes and 
others such as psychological disorders are usual among patients 
with the chronic respiratory disease. Data obtained from the present 
study demonstrated that majority of patients were hypertensive 
(70%); the second most common comorbidity was diabetes mellitus 
(60%). Cardiovascular and psychological disorders accounted for 40 
and 10% of the sample size respectively.  
Statistical analysis of FEV1 and FVC values 
Statistical analysis was carried out for comparing FEV1 and FVC 
values pre-and post-treatment in dual and triple therapies, shown in 
table 1 (a) and (b). 
  
Table 1: Statistical analysis of FVC and FEV1 values in (a) dual therapy and (b) triple therapy 
(a) 
Statistical value Dual therapy 
FVC FEV1 
Pre-treatment Post-treatment Pre-treatment Post-treatment 
Mean 46.70 55.30 46.97 55.83 
(b) 
Statistical value Triple therapy 
FVC FEV1 
Pre-treatment Post-treatment Pre-treatment Post-treatment 
Mean 46.50 61.40 47.10 61.37 
On thoroughly inspecting the data, the difference between the mean of FVC pre-and post-treatment in dual therapy was found to be 8.60 and the 
difference between the mean of FEV1 pre-and post-treatment was calculated as 8.87. In triple therapy, the difference between the mean of FVC pre-
and post-treatment was 14.90 and the difference between the mean of FEV1 pre-and post-treatment was 14.27. 
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Distribution of patients based on disease severity 
For judging the comparative superiority of one drug regimen over 
the other, we graded the disease severity based on specific score 
ranges. Scores of 0-10, 11-20 and 21-30 represented mild, moderate 
or severe disease states respectively. We then compared the score 
ranges pre-and post-treatments in either therapy to make a 
conclusion regarding the efficacy of one over the other. 
Comparative distribution of patient’s pre-and post-treatment 
with dual therapy 
The former group of subjects undergoing dual therapy were 
categorized as mild, moderate and severe, with respect to their 
scores before medication administration. Out of 30 patients, it was 
observed that 36.67% patients suffered from moderate COPD, while 
a majority 63.34% suffered from severe COPD. No mild cases were 
documented.  
Three months post-treatment, the highest cases observed were 
those of moderate COPD (66.67%), followed by mild (20%) and 
severe (13.34%) disease. Table 2 compares the scores of patients 
before and after treatment with dual therapy. 
Clearly, the number of patients with severe illness after therapy was 
found to decrease i.e. 19 cases pre-treatment to 4 cases post-
treatment. There was also a marked decrease in the scores 
calculated from the questionnaire. 
Comparative distribution of patient’s pre-and post-treatment 
with triple therapy 
The latter group of subjects undergoing triple therapy were classed as 
mild, moderate and severe, based on their scores before the onset of 
therapy. From a total of 30 patients, severe cases took the lead 
(66.67%), the successors being moderate (30%) and mild cases 
(3.34%).  
After three months, it was found that 46.67% were moderate, 
43.34% were mild and the least documented were severe cases 
(10%). Table 3 compares the scores of patients before and after 
treatment with triple therapy. 
  
Table 2: Distribution of patients according to their scores before and after treatment with dual therapy 
Score range Scale Number of patients 
 Pre- Post- Difference  
0–10 Mild 0  6 (20%) 6 (20%) 
11–20 Moderate 11 (36.6%) 20 (66.6%) 9 (30%) 
21–30 Severe 19 (63.3%) 4 (13.3%) 15(50%) 
 
Table 3: Distribution of patients according to their scores before and after treatment with triple therapy 
Score range Scale Number of patients 
 Pre- Post- Difference  
0–10 Mild 1 (3.34%) 13 (43.3%) 12(40%) 
11–20 Moderate 9 (30%) 14 (46.6%) 5 (16.67%) 
21–30 Severe 20 (66.6%) 3 (10%) 17(56.67%) 
Follow-up after treatment demonstrated a decrease in the percentage of patients suffering from severe disease. The documented difference 
between the percentages of severe cases pre-and post-treatment was more than 50%. This was coupled with a decrease in the scores calculated 
from the questionnaire.  
 
Table 4: Comparison of scores in dual and triple therapies 
Score range  Dual therapy  Triple therapy  
Scale Number of patients Number of patients 
 Pre- Post- Difference  Pre- Post- Difference  
0–10 Mild 0  6 (20%) 6 (20%) 1 (3.34%) 13 (43.3%) 12(40%) 
11–20 Moderate 11 (36.6%) 20 (66.6%) 9 (30%) 9 (30%) 14 (46.6%) 5 (16.67%) 
21–30 Severe 19 (63.3%) 4 (13.3%) 15(50%) 20 (66.6%) 3 (10%) 17(56.67%) 
 
Comparison of scores in dual and triple therapies 
Comparative analysis between the percentages of pre-and post-
treatment in dual and triple therapies portrayed the following 
conclusions:  
• The difference between the percentages of mild cases pre-and 
post-treatment in dual therapy was found to be 20%; this was 
contrasted with double the increase in triple therapy (40%).  
• The difference between the percentages of moderate cases pre-
and post-treatment in dual therapy was calculated as 30%, in 
contrast to the difference of 16.67% in triple therapy.  
• The difference between the percentages of severe cases pre-and 
post-treatment in dual therapy was calculated as 50%; this was 
contrasted with an increase of 56.67% in triple therapy.  
This indicates that post-treatment, dual therapy administration 
added 6 patients to the mild category, 9 patients to the moderate 
category and eliminated 15 from the severe grade. On the contrary, 
triple regimen added 12 patients to the mild category, 5 patients to 
the moderate category, while eliminating 17 from the severe grade. 
The data is presented in table 4.  
DISCUSSION 
In 2010, an estimated 384 million people suffered from COPD 
globally [9]. In India, about 5 lakh deaths are attributable to the 
disease per year; this means that every minute, one person dies [13]. 
Progressing from dual to triple-drug regimens, the latter have 
proven effective over other drug combinations only recently [14]. 
Our comparative analysis demonstrates a greater increase in the 
differences of means of both FVC (pre-and post-treatment difference 
of 8.60 with dual therapy in contrast to 14.90 with triple regimen) 
and FEV1 (pre-and post-treatment difference of 8.87 with dual 
therapy in contrast to 14.27 with triple therapy) values in patients 
receiving triple-drug combination. It can, therefore, be inferred that 
patients undergoing triple-drug therapy benefitted more than those 
undergoing dual drug combination therapy. 
Our study demonstrates the highest prevalence of the disease in the 
age group of 61-70 y, followed by the range of 51-60 y olds i.e. patients 
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aged between 51 and 70 y constituted the majority (60%) of the 
population. This was probably due to long-term occupational exposure 
and indoor and outdoor pollution [5]. Other studies report a higher 
prevalence in patients aged 70 y and above [15-18], attributing the 
cause to tobacco smoking and advancing age [15]. The least prone was 
the age group of 81-90 y, credited to the healthy survivor effect [15, 
18], in which individuals succumb to death before 80 y of age owing to 
chronicity of the illness and associated comorbidities. 
Gender wise analysis reports a higher preponderance in males 
(63.3%) compared to females (36.67%). This was consistent with 
the results of other researchers [9, 15-18]. A contributing element in 
this regard is habitual smoking in men.  
The current research consisted of 23 male smokers, accounting for 
60.52% of the male population and 38.3% of the total. No female 
smokers were documented. The two most essential etiologic agents 
implicated in COPD are smoking and environmental pollutants [19, 
20]. As men exhibit considerable exposure to either of these, their 
dominance in this respect is clearly comprehensible.  
The GOLD guidelines, however, have stated increasing age and 
female sex as risk factors for COPD [5]. Over the past few decades, 
cigarette smoking by women in developed countries has become 
‘trendy’ [9], leading to more rapidly deteriorating lung function and 
a greater annual decline in FEV1 [21]. This has contributed to a 
notable increase in the incidence of the disease among young 
females aged 50-59 y and above, while prevalence is still dominated 
by males [9, 15-18, 21]. Additionally, recent researches have evinced 
a possible link between COPD and autoimmunity. Consequently, as 
women are more prone to autoimmune disorders, they would 
unambiguously be inclined to develop COPD [21].  
Symptom evaluation revealed that almost all the patients 
experienced cough (93.3%) and dyspnoea (85%). The successors 
were fever (45%) and haemoptysis (15%). While the former two are 
the result of airway obstruction and excessive mucus secretion [22], 
latter manifestations may indicate oncoming respiratory infections. 
However, diagnosis of COPD cannot rely solely on clinical 
manifestations, as a small percentage of patients present with no 
respiratory symptoms at all [15]. The guidelines, therefore, portray 
an organized approach to assessing affected patients [5].  
Association between COPD and comorbidities is complex. Our study 
showed that hypertensive patients constituted 70% of the sample 
total. Diabetes mellitus was the second most prevalent comorbidity. 
This was proceeded by cardiovascular diseases (40%), pneumonia 
(25%) and psychological abnormalities (10%). The co-existence of a 
disease alongside COPD is multifactorial and is ultimately specific to 
the patient [16]. However, several mechanisms have been proposed 
to explain the relation between the two. Impairment of lung function 
due to the chronic illness builds pressure in pulmonary vessels, 
causing pulmonary hypertension. This further increases the 
workload on the heart and may result in the development of 
cardiovascular disorders such as ischemic heart disease, heart 
failure and arrhythmias [23]. Right ventricular failure, if present, 
may remain unaltered despite ongoing treatment [24]. The relation 
between diabetes and COPD is intricate, with each pre-existing 
condition worsening the prognosis of the other. Pre-existing 
diabetes aggravates COPD through direct harmful effects of 
hyperglycaemia on lung function, while pre-existing COPD augments 
diabetes via its deteriorating effects on insulin resistance [25].  
After gauging FEV1 and FVC values before and after treatments, we 
allotted score ranges of 0-10, 11-20 and 21-30 to mild, moderate 
and severe categories and assessed the superiority of one regimen 
over the other. From our observations, we concluded that the 
number of patients suffering from severe COPD decreased 
significantly in triple-drug therapy trial, indicative of its increased 
efficacy over dual-drug regimen. Our findings coincided with those 
of others [26-28]. 
The current research involved administration of triple therapy to 
patients independent of disease severity, in contrast to GOLD 
guidelines which recommend reservation of the triple drug regimen 
for severe cases with frequent exacerbations [14].  
Singh et al. [26] and Cazzola et al. [27] conducted analogous 
researches by comparing triple therapy involving LABA, LAMA and 
ICS with LABA+ICS or LAMA alone. Both the authors reported better 
outcomes with a triple-drug regimen, evident from improvement in 
pulmonary tests. Singh et al. [26] Additionally inferred that triple 
therapy is ineffective with a single dose and that it elicits its 
therapeutic response gradually over a period of two weeks [26]. 
Anticholinergics exert their effects by blocking parasympathetically 
induced bronchoconstriction [12]. They also aid in enhancing FEV1, 
decrease inflation of lungs [26] while minimizing exacerbations [29]. 
While studies claim the efficacy of tiotropium, salmaterol and 
fluticasone to be equal to glycopyrronium, salmaterol and 
fluticasone, there exists minor superiority of the latter in improving 
FEV1 [30] and eliciting peak response with only a single dose [31].  
The use of corticosteroids over longer durations is raising concerns 
owing to its resistance and related adverse effects [29]. Researches 
in this field are ongoing, with trials to replace ICS with the better 
phosphodiesterase-4 inhibitors or other alternatives, where possible 
[12, 14]. 
Limitation of the present study was its small sample size. The study 
was also confined to three months duration and therefore, could not 
address maintenance therapy and associated adverse effects. The 
study also excluded the exacerbations of COPD. 
CONCLUSION  
In conclusion, our data suggested that the triple drug combination of 
formoterol, ciclesonide and tiotropium showed more efficacy in 
patients suffering from COPD than the dual drug combination of 
formoterol and budesonide. The former group was shown to elicit 
its therapeutic response by producing a greater reduction in FVC 
and FEV1 post-treatment. The use of triple therapy also extends in 
reducing the number of patients suffering from severe COPD. It 
demonstrates benefits on lung function and improvement of 
symptoms, thereby enhancing patients’ quality of life. Additionally, 
patients with advanced COPD reported that triple therapy combined 
with pulmonary rehabilitation provided substantial benefit in terms 
of lung function.  
With the present available literature, the question “Is three better 
than two?” seems to be answered with conclusive evidence. The new 
question that arises is “Which three is better?” The search for the 
most effective triple therapy portraying maximal benefits and with 
least documented adverse effects is still ongoing.  
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